Perspectivas del mercado y visión del analista:
Las infecciones adquiridas en hospitales (HAI), también conocidas como infecciones adquiridas nosocomialmente, pueden desarrollarse en una variedad de entornos, incluidos hospitales, instituciones de atención a largo plazo y entornos ambulatorios, y también pueden aparecer después del alta. Las HAI también pueden implicar infecciones ocupacionales que afectan a los trabajadores de la salud. Los factores clave que impulsan el crecimiento del mercado de tratamiento de infecciones adquiridas en hospitales son la alta prevalencia de HAI y el creciente enfoque en la seguridad del paciente y la atención de calidad. Sin embargo, la amenaza de la resistencia a los antimicrobianos obstaculiza el crecimiento del mercado de tratamiento de infecciones adquiridas en hospitales.
Impulsores y restricciones del crecimiento:
Las infecciones del torrente sanguíneo asociadas a catéteres, las infecciones del tracto urinario asociadas a catéteres y la neumonía asociada a ventiladores son algunos ejemplos de Infecciones asociadas a la atención sanitaria (IAAS). Estas infecciones, conocidas como infecciones del sitio quirúrgico, también pueden surgir en los sitios quirúrgicos. Según el informe de los Centros para el Control y la Prevención de Enfermedades (CDC) “Informe de progreso de las infecciones asociadas a la atención médica nacional y estatal de 2020" publicado en 2021, los casos de infecciones del torrente sanguíneo asociadas a vías centrales, bacteriemia por Staphylococcus aureus resistente a la meticilina (MRSA) y ventilador -Los eventos asociados aumentaron en un 24 %, 35 % y 15 %, respectivamente, en los EE. UU. entre 2019 y 2020.
Además, según el informe de enero de 2022 de la Red Nacional de Seguridad Sanitaria (NHSN), las infecciones del tracto urinario ( Las infecciones urinarias son el quinto tipo más común de infección asociada a la atención médica. Las infecciones urinarias representan más del 9,5% de las afecciones hospitalarias de cuidados intensivos. La infección del tracto urinario asociada al catéter (IACU) es causada por catéteres urinarios utilizados para drenar la orina de la vejiga. es una de las infecciones más frecuentes entre los pacientes hospitalizados con ITU. Según los Centros para el Control y la Prevención de Enfermedades (CDC), casi el 75% de las infecciones están relacionadas con un catéter urinario. Durante su estancia en el hospital, entre el 15% y el 25% de los pacientes hospitalizados necesidad de utilizar catéteres urinarios. El uso prolongado de catéter urinario es el factor de riesgo más importante para contraer CAUTI. Las complicaciones de las CAUTI implican sufrimiento para el paciente, estancias hospitalarias prolongadas, mayores costos de tratamiento e incluso la muerte.
Además, según los CDC, las infecciones urinarias son responsables de más de 13.000 muertes cada año. La cistitis aguda no complicada causa alrededor de seis días de malestar, lo que resulta en aproximadamente 7 millones de visitas al consultorio cada año con un costo de 1.600 millones de dólares. Como resultado, el creciente número de casos de HAI supone una carga financiera importante para el sistema sanitario. La creciente prevalencia de CAUTI, combinada con la mayor demanda de medicamentos para el tratamiento, está impulsando el mercado. Sin embargo, la resistencia a los antimicrobianos plantea un desafío importante para el tratamiento de HAI, limitando la eficacia de los agentes antimicrobianos existentes y requiriendo el desarrollo de nuevos tratamientos. estrategias y alternativas antimicrobianas para combatir eficazmente los patógenos resistentes.
Perspectivas estratégicas
Segmentación y alcance del informe:
El mercado mundial de tratamiento de infecciones adquiridas en hospitales está segmentado según la clase de medicamento, el tipo de infección y el canal de distribución. Según la clase de medicamento, el mercado de tratamiento de infecciones adquiridas en hospitales se segmenta en medicamentos antibacterianos, antivirales, antimicóticos y otros. Según el tipo de infección, el tratamiento de las infecciones adquiridas en el hospital se diferencia en infecciones del tracto urinario, neumonía asociada al ventilador, infecciones del sitio quirúrgico, infecciones del torrente sanguíneo y otras infecciones hospitalarias. Según el canal de distribución, el mercado se segmenta en farmacias hospitalarias, farmacias minoristas, comercio electrónico y otros. El mercado de tratamiento de infecciones adquiridas en hospitales, según la geografía, está segmentado en América del Norte (EE. UU., Canadá y México), Europa (Alemania, Francia, Italia, Reino Unido, Rusia y el resto de Europa), Asia Pacífico (Australia , China, Japón, India, Corea del Sur y el resto de Asia Pacífico), Medio Oriente y África (Sudáfrica, Arabia Saudita, Emiratos Árabes Unidos y el resto de Medio Oriente y África) y América del Sur y Central (Brasil , Argentina y el resto de América del Sur y Central).
Análisis segmentario:
El mercado de tratamiento de infecciones adquiridas en hospitales, por clase de medicamento, se segmenta en medicamentos antibacterianos, medicamentos antivirales, medicamentos antimicóticos y otros. El segmento de medicamentos antibacterianos tuvo la mayor participación de mercado en 2022 y se prevé que registre la CAGR más alta durante 2022-2030.
Mercado de tratamiento de infecciones adquiridas en hospitales, por clase de medicamento – 2022 y 2030
El mercado de tratamiento de infecciones adquiridas en hospitales, por tipo de infección, se segmenta en infecciones del tracto urinario, neumonía asociada a ventilador, infecciones del sitio quirúrgico, infecciones del torrente sanguíneo y otras infecciones hospitalarias. El segmento de infecciones del tracto urinario tuvo la mayor participación de mercado en 2022. Sin embargo, se prevé que el segmento de neumonía asociada a ventilador registre la CAGR más alta de 2022 a 2030.
El mercado de tratamiento de infecciones adquiridas en hospitales, por canal de distribución, se segmenta en farmacias hospitalarias, farmacias minoristas, comercio electrónico y otros. En 2022, el segmento de farmacias hospitalarias tuvo la mayor participación de mercado y se prevé que el mismo segmento registre la CAGR más alta durante 2022-2030.
Análisis regional:
Según la geografía, el mercado mundial de tratamiento de infecciones adquiridas en hospitales es segmentado en cinco regiones clave: América del Norte, Europa, Asia Pacífico, América del Sur y Central, y Medio Oriente y África.
En 2022, América del Norte tenía la mayor participación del tamaño del mercado mundial de tratamiento de infecciones adquiridas en hospitales. Estados Unidos tiene una alta prevalencia de HAI, lo que impulsa el crecimiento del mercado de tratamiento de infecciones adquiridas en hospitales. Según los CDC, en un día cualquiera, aproximadamente 1 de cada 31 pacientes hospitalizados tiene al menos una HAI. De manera similar, según la Oficina de Prevención de Enfermedades y Promoción de la Salud, las HAI y otras infecciones pueden provocar sepsis, y causan aproximadamente 1,7 millones de casos de enfermedad y 270.000 muertes por año en los EE. UU. Por lo tanto, la alta prevalencia de HAI entre las personas en los EE. UU. impulsa el crecimiento del mercado de tratamiento de infecciones adquiridas en hospitales.
Desarrollos de la industria y oportunidades futuras:
A continuación se enumeran varias iniciativas tomadas por actores clave que operan en el mercado global de tratamiento de infecciones adquiridas en hospitales:
En mayo de 2023, Innoviva Specialty Therapeutics anunció que la Administración de Alimentos y Medicamentos de EE. UU. ( FDA) había aprobado XACDURO (sulbactam inyectable; durlobactam inyectable), empaquetado conjuntamente para uso intravenoso en pacientes de 18 años o más para el tratamiento de la neumonía bacteriana adquirida en el hospital y la neumonía bacteriana asociada al ventilador (HABP/VABP) causada por aislados susceptibles del complejo Acinetobacter baumannii-calcoaceticus (Acinetobacter). Innoviva Specialty Therapeutics declaró que se centra en brindar terapias innovadoras en cuidados críticos y enfermedades infecciosas. En mayo de 2023, investigadores del Instituto Indio de Investigación y Educación Científica (IISER), Pune y el Instituto Central de Investigación de Medicamentos (CSIR-CDRI), Lucknow anunciaron que habían descubierto un nuevo antibiótico potencial contra Acinetobacter baumannii, que frecuentemente causa HAI. En septiembre de 2020, Shionogi & Co Ltd anunció que la FDA había aprobado una Solicitud de Nuevo Medicamento (sNDA) complementaria para FETROJA (cefiderocol) para el tratamiento de pacientes. mayores de 18 años con neumonía bacteriana adquirida en el hospital y neumonía bacteriana asociada a la ventilación mecánica (HABP/VABP) causada por microorganismos gramnegativos susceptibles como el complejo Enterobacter cloacae, Klebsiella pneumoniae, el complejo Acinetobacter baumannii, Escherichia coli, Pseudomonas aeruginosa y Serratia marcescens.En junio de 2020, Merck anunció que la Administración de Medicamentos y Alimentos de EE. UU. (FDA) había aprobado una Solicitud de Nuevo Fármaco (sNDA) complementaria para RECARBRIO (imipenem, cilastatina y relebactam) para el tratamiento de pacientes de 18 años o más que padecen neumonía bacteriana adquirida en el hospital y neumonía bacteriana asociada al ventilador (HABP/VABP), causada por microorganismos gramnegativos susceptibles como el complejo Acinetobacter calcoaceticus-baumannii, Klebsiella oxytoca, Klebsiella pneumoniae, Enterobacter cloacae, Escherichia coli, Haemophilus influenzae, Klebsiella aerogenes, Pseudomonas aeruginosa y Serratia marcescens. Panorama competitivo y empresas clave:
Merck & Co Inc, Pfizer Inc, AbbVie Inc, Paratek Pharmaceuticals Inc, Eugia US LLC, Abbott Laboratories, Cumberland Pharmaceuticals Inc, Innoviva Specialty Therapeutics Inc, Cipla Ltd, y Eli Lilly and Company se encuentran entre los actores destacados que operan en el mercado de tratamiento de infecciones adquiridas en hospitales. Estas empresas se centran en nuevas tecnologías, avances en productos existentes y expansiones geográficas para satisfacer la creciente demanda de los consumidores en todo el mundo y aumentar su gama de productos en carteras especializadas.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The hospital acquired infection treatment market, by distribution channel, is segmented into hospital pharmacies, retail pharmacies, e-commerce, and others. In 2022, the hospitals pharmacies segment held the largest market share, and the same segment is anticipated to register the highest CAGR during 2022–2030.
The hospital acquired infection treatment market, by infection type, is segmented into urinary tract infections, ventilator-associated pneumonia, surgical site infections, bloodstream infections, and other hospital infections. The urinary tract infections segment held a larger market share in 2022; However, the ventilator-associated pneumonia segment is anticipated to register a higher CAGR during 2022-2030.
The hospital acquired infection treatment market, by drug class, is segmented into antibacterial drugs, antiviral drugs, antifungal drugs, and others. The antibacterial drugs segment held a larger market share in 2022, and the same segment is anticipated to register a higher CAGR during 2022-2030.
The hospital acquired infection treatment market is expected to be valued at US$ 19,978.39 million in 2030.
The hospital acquired infection treatment market was valued at US$ 15,099.19 million in 2022.
Key factors driving the hospital acquired infection treatment market growth include the high prevalence of hospital-acquired infections (HAI) and the growing focus on patient safety and quality care.
The hospital acquired infection treatment market majorly consists of the players, including Merck & Co Inc, Pfizer Inc, AbbVie Inc, Paratek Pharmaceuticals Inc, Eugia US LLC, Abbott Laboratories, Cumberland Pharmaceuticals Inc, Innoviva Specialty Therapeutics Inc, Cipla Ltd, and Eli Lilly and Company.
Hospital-acquired infections (HAI), also known as nosocomially acquired infections. HAIs are infections acquired during medical treatment that were not present at the time of admission. They may develop in a variety of settings, including hospitals, long-term care institutions, and ambulatory settings, and they can also appear after discharge. HAIs can also involve occupational infections that affect healthcare workers.
The List of Companies - Hospital Acquired Infection Treatment Market
- Merck & Co Inc
- Pfizer Inc
- AbbVie Inc
- Paratek Pharmaceuticals Inc
- Eugia US LLC
- Abbott Laboratories
- Cumberland Pharmaceuticals Inc
- Innoviva Specialty Therapeutics Inc
- Cipla Ltd
- Eli Lilly and Company
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Dec 2023
Aquatic Veterinary Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Diagnostics and Treatments), Species (Fish, Crustaceans, Mollusca, and Others), Disease Source (Bacteria, Viruses, Parasites, and Others), Route of Administration (Water Medication, Medicated Feed, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Dec 2023
Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (Generic Drugs and Originators), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Dec 2023
Malaria and Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Dec 2023
Pharmaceutical Contract Sales Organizations Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services (Commercial Services and Non-Commercial Services), Modules (Syndicated Modules and Dedicated Modules), Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others), End User (Biopharmaceutical Companies and Pharmaceutical Companies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Dec 2023
Breast Cancer Therapeutics Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Dec 2023
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Dec 2023
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Dec 2023
Hyperpigmentation Disorder Treatment Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment Type (Cosmeceutical, Light or Laser Therapy, Microdermabrasion, Chemical Peels, Cryotherapy, and Others), Condition (Melasma, Solar Lentigines, Post-Inflammatory Hyperpigmentation, and Others), End User (Hospitals, Dermatology Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)